Gout: Where Is the Weak Link?
Journal
Journal of clinical rheumatology : practical reports on rheumatic & musculoskeletal diseases
ISSN: 1536-7355
Titre abrégé: J Clin Rheumatol
Pays: United States
ID NLM: 9518034
Informations de publication
Date de publication:
Aug 2020
Aug 2020
Historique:
pubmed:
23
7
2020
medline:
1
6
2021
entrez:
23
7
2020
Statut:
ppublish
Résumé
In the field of rheumatic and musculoskeletal diseases, no other condition has evolved so significantly since the mid-1950s as gout. In this period, the cause of gout has been firmly established; the close relationship with other conditions clarified; a rapid, unequivocal diagnostic test established; and agents effective in dissolving monosodium urate crystals and controlling inflammation made widely available. All these insights have ultimately led to deem gout as curable, an end point formerly considered out of reach. Unfortunately, diagnosis and management of gout in clinical practice have not paralleled the scientific advances and remain far from established quality standards. This paradox is the topic of the present review article, intending to increase the widespread interest of clinicians in gout.
Identifiants
pubmed: 32694357
doi: 10.1097/RHU.0000000000001492
pii: 00124743-202008000-00008
doi:
Substances chimiques
Gout Suppressants
0
Uric Acid
268B43MJ25
Types de publication
Journal Article
Review
Langues
eng
Sous-ensembles de citation
IM
Pagination
208-212Références
Yü T, Yu TF. Milestones in the treatment of gout. Am J Med. 1974;56:676–685.
Pearce J. Tsai-Fan Yu, 95, physician, dies; helped alleviate gout. Available at: https://www.nytimes.com/2007/03/12/obituaries/12yu.html. Accessed March 18, 2020.
Yu TF, Gutman AB. Mobilization of gouty tophi by protracted use of uricosuric agents. Am J Med. 1951;11:765–769.
Friedlander RD. Cortisone as an adjunct in the therapy of acute gout. J Am Med Assoc. 1951;145:11–14.
Gutman AB, Yu TF. Effects of adrenocorticotropic hormone in gout. Am J Med. 1950;9:24–30.
Kuzell WC, Schaffarzick RW, Brown B, et al. Phenylbutazone (butazolidin) in rheumatoid arthritis and gout. J Am Med Assoc. 1952;149:729–734.
Smyth CJ, Velayos EE, Amoroso C. Influence of new anti-inflammatory drug: indomethacin in acute gout. Acta Rheum Stand. 1963;9:306.
Yu TF, Gutman AB. Efficacy of colchicine prophylaxis in gout. Prevention of recurrent gouty arthritis over a mean period of five years in 208 gouty subjects. Ann Intern Med. 1961;55:179–192.
Rundles RW, Wyngaarden JB, Hitchings GH, et al. Effects of a xanthine oxidase inhibitor on thiopurine metabolism, HU and gout. Trans Assoc Am Phys. 1963;76:126.
McCarty DJ, Hollander JL. Identification of urate crystals in gouty synovial fluid. Ann Intern Med. 1961;54:452–460.
McCarty DJ Jr. Mechanisms of the crystal deposition diseases—gout and pseudogout. Ann Intern Med. 1973;78:767–771.
Pascual E. Persistence of monosodium urate crystals, and low grade inflammation in the synovial fluid of untreated gout. Arthritis Rheum. 1991;34:141–145.
Pascual E, Batlle-Gualda E, Martínez A, et al. Synovial fluid analysis for diagnosis of intercritical gout. Ann Intern Med. 1999;131:756–759.
Pascual E, Addadi L, Andrés M, et al. Mechanisms of crystal formation in gout—a structural approach. Nat Rev Rheumatol. 2015;11:725–730.
Dalbeth N, Pool B, Gamble GD, et al. Cellular characterization of the gouty tophus: a quantitative analysis. Arthritis Rheum. 2010;62:1549–1556.
Pérez Ruiz F, Calabozo M, Pijoan JI, et al. Effect of urate-lowering therapy on the velocity of size reduction of tophi in chronic gout. Arthritis Rheum. 2002;47:356–360.
Zhang W, Doherty M, Bardin T, et al. EULAR evidence based recommendations for gout. Part II: management. Report of a task force of the EULAR Standing Committee for International Clinical Studies Including Therapeutics (ESCISIT). Ann Rheum Dis. 2006;65:1312–1324.
Martinon F, Petrilli V, Mayor A, et al. Gout-associated uric acid crystals activate the NALP3 inflammasome. Nature. 2006;440:237–241.
Sivera F, Wechalekar MD, Andrés M, et al. Interleukin-1 inhibitors for acute gout. Cochrane Database Syst Rev. 2014;CD009993.
Landis RC, Yagnik DR, Florey O, et al. Safe disposal of inflammatory monosodium urate monohydrate crystals by differentiated macrophages. Arthritis Rheum. 2002;46:3026–3033.
Scanu A, Oliviero F, Ramonda R, et al. Cytokine levels in human synovial fluid during the different stages of acute gout: role of transforming growth factor β1 in the resolution phase. Ann Rheum Dis. 2012;71:621–624.
Ottaviani S, Allard A, Bardin T, et al. An exploratory ultrasound study of early gout. Clin Exp Rheumatol. 2011;29:816–821.
Yokose C, Dalbeth N, Wei J, et al. Radiologic evidence of symmetric and polyarticular monosodium urate crystal deposition in gout—a cluster pattern analysis of dual-energy CT. Semin Arthritis Rheum. 2020;50:54–58.
Steinberg GL. Gout and its effect on the cardiovascular system. Ann Rheum Dis. 1945;4:51–53.
Hill LC. Review of gout, 1939–1946. Ann Rheum Dis. 1946;5:171–176.
Haller H. Epidermiology and associated risk factors of hyperlipoproteinemia. Z Gesamte Inn Med. 1977;32:124–128.
Krishnan E, Baker JF, Furst DE, et al. Gout and the risk of acute myocardial infarction. Arthritis Rheum. 2006;54:2688–2696.
Choi HK, Curhan G. Independent impact of gout on mortality and risk for coronary heart disease. Circulation. 2007;116:894–900.
Clarson LE, Chandratre P, Hider SL, et al. Increased cardiovascular mortality associated with gout: a systematic review and meta-analysis. Eur J Prev Cardiol. 2015;22:335–343.
Klauser AS, Halpern EJ, Strobl S, et al. Dual-energy computed tomography detection of cardiovascular monosodium urate deposits in patients with gout. JAMA Cardiol. 2019;4:1019–1028.
Roughley M, Sultan AA, Clarson L, et al. Risk of chronic kidney disease in patients with gout and the impact of urate lowering therapy: a population-based cohort study. Arthritis Res Ther. 2018;20:243.
Verger D, Leroux-Robert C, Ganter P, et al. Gouty tophi in the renal medulla in chronic uremia. Study of 17 cases discovered from among 62 autopsies. Nephron. 1967;4:356–370.
Linnane JW, Burry AF, Emmerson BT. Urate deposits in the renal medulla. Prevalence and associations. Nephron. 1981;29:216–222.
Ayoub I, Almaani S, Brodsky S, et al. Revisiting medullary tophi: a link between uric acid and progressive chronic kidney disease? Clin Nephrol. 2016;85:109–113.
Bardin T, Tran KM, Nguyen QD, et al. Renal medulla in severe gout: typical findings on ultrasonography and dual-energy CT study in two patients. Ann Rheum Dis. 2019;78:433–434.
Chen JH, Lan JL, Cheng CF, et al. Effect of urate-lowering therapy on the risk of cardiovascular disease and all-cause mortality in patients with gout: a case-matched cohort study. J Rheumatol. 2015;42:1694–1701.
Pérez Ruiz F, Richette P, Stack AG, et al. Failure to reach uric acid target of <0.36 mmol/L in hyperuricaemia of gout is associated with elevated total and cardiovascular mortality. RMD Open. 2019;5:e001015.
Novella-Navarro M, Cabrera-Alarcon JL, Diaz-Torne C, et al. A treat-to-target approach for gout confers renoprotective effect in patients with chronic kidney disease stage 3. Rheumatol Int. 2020.
Stewart S, Maxwell H, Dalbeth N. Prevalence and discrimination of OMERACT-defined elementary ultrasound lesions of gout in people with asymptomatic hyperuricaemia: a systematic review and meta-analysis. Semin Arthritis Rheum. 2019;49:62–73.
de Mello FM, Helito PV, Bordalo-Rodrigues M, et al. Axial gout is frequently associated with the presence of current tophi, although not with spinal symptoms. Spine (Phila Pa 1976). 2014;39:E1531–E1536.
Carr A, Doyle AJ, Dalbeth N, et al. Dual-energy CT of urate deposits in costal cartilage and intervertebral disks of patients with tophaceous gout and age-matched controls. AJR Am J Roentgenol. 2016;206:1063–1067.
Gerster JC, Landry M, Rappoport G, et al. Enthesopathy and tendinopathy in gout: computed tomographic assessment. Ann Rheum Dis. 1996;55:921–923.
Huang HC, Chiang HP, Hsu NW, et al. Differential risk group of developing stroke among older women with gouty arthritis: a latent transition analysis. Eur J Clin Invest. 2019;49:e13090.
De Miguel E, Puig JG, Castillo C, et al. Diagnosis of gout in patients with asymptomatic hyperuricaemia: a pilot ultrasound study. Ann Rheum Dis. 2012;71:157–158.
Abhishek A, Courtney P, Jenkins W, et al. Brief report: monosodium urate monohydrate crystal deposits are common in asymptomatic sons of patients with gout: the Sons of Gout Study. Arthritis Rheumatol. 2018;70:1847–1852.
Bardin T, Richette P. Impact of comorbidities on gout and hyperuricaemia: an update on prevalence and treatment options. BMC Med. 2017;15:123.
Andrés M, Quintanilla MA, Sivera F, et al. Silent monosodium urate crystal deposits are associated with severe coronary calcification in asymptomatic hyperuricemia: an exploratory study. Arthritis Rheumatol. 2016;68:1531–1539.
Sivera F, Andrés M, Carmona L, et al. Multinational evidence-based recommendations for the diagnosis and management of gout: integrating systematic literature review and expert opinion of a broad panel of rheumatologists in the 3e Initiative. Ann Rheum Dis. 2014;73:328–335.
Richette P, Doherty M, Pascual E, et al. 2018 Updated European League Against Rheumatism evidence-based recommendations for the diagnosis of gout. Ann Rheum Dis. 2020;79:31–38.
Lumbreras B, Pascual E, Frasquet J, et al. Analysis for crystals in synovial fluid: training of the analysts results in high consistency. Ann Rheum Dis. 2005;64:612–615.
Malik A, Schumacher HR, Dinnella JE, et al. Clinical diagnostic criteria for gout: comparison with the gold standard of synovial fluid crystal analysis. J Clin Rheumatol. 2009;15:22–24.
Sivera F, Andres M, Falzon L, et al. Diagnostic value of clinical, laboratory, and imaging findings in patients with a clinical suspicion of gout: a systematic literature review. J Rheumatol Suppl. 2014;92:3–8.
Perez Ruiz F, Sanchez-Piedra CA, Sanchez-Costa JT, et al. Improvement in diagnosis and treat-to-target management of hyperuricemia in gout: results from the GEMA-2 Transversal Study on Practice. Rheumatol Ther. 2018;5:243–253.
Roddy E, Packman J, Obrenovic K, et al. Management of gout by UK rheumatologists: a British Society for Rheumatology National Audit. Rheumatology (Oxford). 2018;57:826–830.
Katayama A, Yokokawa H, Fukuda H, et al. Achievement of target serum uric acid levels and factors associated with therapeutic failure among Japanese men treated for hyperuricemia/gout. Intern Med. 2019;58:1225–1231.
Edwards NL, Schlesinger N, Clark S, et al. Management of gout in the United States: a claims-based analysis. ACR Open Rheumatol. 2020;2:180–187.
Roddy E, Mallen CD, Hider AL, et al. Prescription and comorbidity screening following consultation for acute gout in primary care. Rheumatology (Oxford). 2010;49:105–111.
Singh JA, Yang S, Saag KG. Factors influencing the effectiveness of allopurinol in achieving and sustaining target serum urate in a US Veterans Affairs gout cohort. J Rheumatol. 2020;47:449–460.
Qaseem A, Harris RP, Forciea MA, et al. Management of acute and recurrent gout: a clinical practice guidelines from the American College of Physicians. Ann Intern Med. 2017;166:56–88.
Dalbeth N, Bardin T, Doherty M, et al. Discordant American College of Physicians and international rheumatology guidelines for gout management: consensus statement of the Gout, Hyperuricemia and Crystal-Associated Disease Network (G-CAN). Nat Rev Rheumatol. 2017;13:561–568.
Fisher MC, Rai SK, Lu N, et al. The unclosing premature mortality gap in gout: a general population-based study. Ann Rheum Dis. 2017;76:1289–1294.
Rees F, Jenkins W, Doherty M. Patients with gout adhere to curative treatment if informed appropriately: proof-of-concept observational study. Ann Rheum Dis. 2013;72:826–830.
Doherty M, Jenkins W, Richardson H, et al. Efficacy and cost-effectiveness of nurse-led care involving education and engagement of patients and a treat-to-target urate-lowering strategy versus usual care for gout: a randomised controlled trial. Lancet. 2018;392:1403–1412.